Management of rheumatoid arthritis in People’s Republic of China – focus on tocilizumab and patient considerations

References

• MiossecPRheumatoid arthritis: still a chronic diseaseLancet2013381987088488623332235
   PubMed Web of Science ®Google Scholar
• LiRSunJRenLMEpidemiology of eight common rheumatic diseases in China: a large-scale cross-sectional survey in BeijingRheumatology (Oxford)201251472172922179737
   PubMed Web of Science ®Google Scholar
• ScottDLWolfeFHuizingaTWRheumatoid arthritisLancet201037697461094110820870100
   PubMed Web of Science ®Google Scholar
• WangXRSuYAnY我国风湿关节炎患者应用肿瘤坏死因子 抑制剂现况调查. [Survey of tumor necrosis factor inhibitors application in patients with rheumatoid arthritis in China]Beijing Da Xue Xue Bao2012442182187 Chinese22516984
   PubMedGoogle Scholar
• HashizumeMTanSLTakanoJTocilizumab, a humanized anti-IL-6R antibody, as an emerging therapeutic option for rheumatoid arthritis: molecular and cellular mechanistic insightsInt Rev Immunol Epub201486
   Web of Science ®Google Scholar
• AkiraSTagaTKishimotoTInterleukin-6 in biology and medicineAdv Immunol1993541788379461
   PubMed Web of Science ®Google Scholar
• YaoXHuangJZhongHTargeting interleukin-6 in inflammatory autoimmune diseases and cancersPharmacol Ther2014141212513924076269
   PubMed Web of Science ®Google Scholar
• NauglerWEKarinMThe wolf in sheep’s clothing: the role of interleukin-6 in immunity, inflammation and cancerTrends Mol Med200814310911918261959
   PubMed Web of Science ®Google Scholar
• NakaharaHSongJSugimotoMAnti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritisArthritis Rheum20034861521152912794819
   PubMed Web of Science ®Google Scholar
• TanakaTNarazakiMKishimotoTTherapeutic targeting of the interleukin-6 receptorAnnu Rev Pharmacol Toxicol20125219921921910626
   PubMed Web of Science ®Google Scholar
• VenkiteshwaranATocilizumabMAbs20091543243820065633
   PubMed Web of Science ®Google Scholar
• SatoKTsuchiyaMSaldanhaJReshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growthCancer Res19935348518568428365
   PubMed Web of Science ®Google Scholar
• MokCCTamLSChanTHLeeGKLiEKManagement of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of RheumatologyClin Rheumatol201130330331221046421
   PubMed Web of Science ®Google Scholar
• NishimotoNYoshizakiKMaedaKToxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical studyJ Rheumatol20033071426143512858437
   PubMed Web of Science ®Google Scholar
• OldfieldVDhillonSPloskerGLTocilizumab: a review of its use in the management of rheumatoid arthritisDrugs200969560963219368420
   PubMed Web of Science ®Google Scholar
• ZhangXChenYCFettnerSPharmacokinetics and pharmacodynamics of tocilizumab after subcutaneous administration in patients with rheumatoid arthritisInt J Clin Pharmacol Ther201351862063023782588
   PubMed Web of Science ®Google Scholar
• OhtaSTsuruTTeraoKMechanism-based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study)J Clin Pharmacol201454110911924115082
   PubMed Web of Science ®Google Scholar
• OgataATanimuraKSugimotoTMusashi Study InvestigatorsPhase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritisArthritis Care Res (Hoboken)201466334435423983039
   PubMed Web of Science ®Google Scholar
• ClinicalTrialgov [homepage on the Internet]US the National Library of Medicine (NLM)2014 [updated August 26, 2014; cited August 29, 2014]. Available from: http://www.clinicaltrials.gov/Accessed August 29, 2014
   Google Scholar
• FleischmannRMHallandAMBrzoskoMTocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year resultsJ Rheumatol201340211312623322466
   PubMed Web of Science ®Google Scholar
• GenoveseMCMcKayJDNasonovELInterleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy studyArthritis Rheum200858102968298018821691
   PubMed Web of Science ®Google Scholar
• JonesGSebbaAGuJComparison of tocilizumab mono-therapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION studyAnn Rheum Dis2010691889619297346
   PubMed Web of Science ®Google Scholar
• SmolenJSBeaulieuARubbert-RothAOPTION InvestigatorsEffect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trialLancet2008371961798799718358926
   PubMed Web of Science ®Google Scholar
• SinghJABegSLopez-OlivoMATocilizumab for rheumatoid arthritisCochrane Database Syst Rev20107CD00833120614469
   PubMed Web of Science ®Google Scholar
• NishimotoNHashimotoJMiyasakaNStudy of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumabAnn Rheum Dis20076691162116717485422
   PubMed Web of Science ®Google Scholar
• EmeryPSebbaAHuizingaTWBiologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritisAnn Rheum Dis201372121897190423918035
   PubMed Web of Science ®Google Scholar
• GabayCEmeryPvan VollenhovenRADACTA Study InvestigatorsTocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trialLancet201338198771541155023515142
   PubMed Web of Science ®Google Scholar
• SmolenJSLandewéRBreedveldFCEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 updateAnn Rheum Dis201473349250924161836
   PubMed Web of Science ®Google Scholar
• ZhangWShiQWuDHEfficacy and safety of infliximab in patients with rheumatoid arthritisZhonghua Yi Xue Za Zhi200989271876188019953907
   PubMedGoogle Scholar
• SinghJAWellsGAChristensenRAdverse effects of biologics: a network meta-analysis and Cochrane overviewCochrane Database Syst Rev20112CD00879421328309
   PubMed Web of Science ®Google Scholar
• MainiRNTaylorPCSzechinskiJCHARISMA Study GroupDouble-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexateArthritis Rheum20065492817282916947782
   PubMed Web of Science ®Google Scholar
• HenniganSKavanaughAInterleukin-6 inhibitors in the treatment of rheumatoid arthritisTher Clin Risk Manag20084476777519209259
   PubMedGoogle Scholar
• ShiQZhaoYBaoCDThe efficacy and safety of tocilizumab combined with disease-modifying anti-rheumatoid drugs in the treatment of active rheumatoid arthritis: a multi-center, randomized, double-blinded, placebo-controlled trialZhonghua Nei Ke Za Zhi201352432332923925361
   PubMedGoogle Scholar
• Lopez-OlivoMATayarJHMartinez-LopezJARisk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysisJAMA2012308989890822948700
   PubMed Web of Science ®Google Scholar
• NishimotoNInterleukin-6 in rheumatoid arthritisCurr Opin Rheumatol200618327728116582692
   PubMed Web of Science ®Google Scholar
• LangleyPCMuRWuMDongPTangBThe impact of rheumatoid arthritis on the burden of disease in urban ChinaJ Med Econ201114670971921899486
   PubMedGoogle Scholar
• StrandVSinghJANewer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivityDrugs201070212114520108988
   PubMed Web of Science ®Google Scholar
• FriesJFSpitzPKrainesRGHolmanHRMeasurement of patient outcomes in arthritisArthritis Rheum198023231371457362664
   PubMed Web of Science ®Google Scholar
• SongYZhuLAWangSLLengLBucalaRLuLJMulti-dimensional health assessment questionnaire in china: reliability, validity and clinical value in patients with rheumatoid arthritisPLoS One201495e9795224848431
   PubMed Web of Science ®Google Scholar
• SmolenJSSchoelsMMNishimotoNConsensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditionsAnn Rheum Dis201372448249223172750
   PubMed Web of Science ®Google Scholar
• KremerJMBlancoRBrzoskoMTocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one yearArthritis Rheum201163360962121360490
   PubMed Web of Science ®Google Scholar
• StrandVBurmesterGROgaleSDevenportJJohnAEmeryPImprovements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE studyRheumatology (Oxford)201251101860186922753773
   PubMed Web of Science ®Google Scholar
• NishimotoNMiyasakaNYamamotoKStudy of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapyMod Rheumatol2009191121918979150
   PubMed Web of Science ®Google Scholar
• DhillonSIntravenous tocilizumab: a review of its use in adults with rheumatoid arthritisBioDrugs20142817510624255004
   PubMed Web of Science ®Google Scholar